Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Account Payables: 2009-2024

Historic Change in Account Payables for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$4.5 million.

  • Cytokinetics' Change in Account Payables rose 284.27% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 431.60%. This contributed to the annual value of -$4.5 million for FY2024, which is 28.71% down from last year.
  • Latest data reveals that Cytokinetics reported Change in Account Payables of -$4.5 million as of FY2024, which was down 28.71% from -$3.5 million recorded in FY2023.
  • Cytokinetics' Change in Account Payables' 5-year high stood at $4.5 million during FY2022, with a 5-year trough of -$4.5 million in FY2024.
  • In the last 3 years, Cytokinetics' Change in Account Payables had a median value of -$3.5 million in 2023 and averaged -$1.1 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 1,059.09% in 2021, then slumped by 176.99% in 2023.
  • Cytokinetics' Change in Account Payables (Yearly) stood at -$110,000 in 2020, then skyrocketed by 1,059.09% to $1.1 million in 2021, then surged by 328.82% to $4.5 million in 2022, then crashed by 176.99% to -$3.5 million in 2023, then decreased by 28.71% to -$4.5 million in 2024.